Stanford Medicine's Jeffrey Goldberg believes a young, underexplored class of therapies called gliotherapeutics, which target and harness glia, will ultimately provide important new directions for treatment.
Not all about neurons: A new avenue for treating neurodegeneration, injury
Stanford Medicine's Jeffrey Goldberg believes a young, underexplored class of therapies called gliotherapeutics, which target and harness glia, will ultimately provide important new directions for treatment.